|
|
 |
|
Viewing report
|
|
|
|
CNS Generic Drugs: Prospects and Opportunities to 2012
Espicom Business Intelligence Ltd, April 2008, Pages: 290
One of the fastest growing drug sectors in terms of product and market value, CNS presents the generics industry with much needed on-going product opportunities
ANTIDEPRESSANTS
Antidepressant sales in 2005 were approximately US$16.2 billion, and accounted for around 25% of the total CNS market. Global sales of the depression drugs analysed in this report in 2006 were worth some US$11.5 billion, with the largest selling, Effexor (venlafaxine), seeing sales worth US$3.7 billion. However, Effexor is now open to generic competition in the United States, with Teva having had an ANDA approved in 2006, and so it is likely that sales of the branded version will decline.
SCHIZOPHRENIA
Sales of schizophrenia drugs in 2005 were worth some US$15.5 billion, accounting for 23% of global CNS sales, making the segment the second largest CNS category. Global sales in 2006 of the schizophrenia drugs listed in this report were worth US$9.7 billion, with Zyprexa (olanzapine) and Risperdal (risperidone) accounting for US$4.4 billion and US$4.2 billion of this, respectively. Currently there are no generic equivalents to any of the schizophrenia drugs listed in the report in the US. However, a number of ANDAs for generic versions of Zyprexa and Risperdal have been tentatively approved.
NEURODEGENERATION
(ALZHEIMER’S DISEASE & PARKINSON’S DISEASE)
The neurodegenerative disorders segment is divided into two components, drugs for treating Alzheimer’s disease, and drugs for treating Parkinson’s disease. In 2005, some US$6.8 billion was spent on treatments for these two conditions, despite the fact that they only affect around 1% of the world’s population. In 2006, global sales of the five Alzheimer’s disease drugs listed in this report were worth some US$1.6 billion, whilst those for treating Parkinson’s disease were worth some US$1.5 billion.
MULTIPLE SCLEROSIS
The multiple sclerosis market was estimated to be worth some US$$4.8 billion in 2005. Global sales of the MS drugs listed in this report in 2006 were worth some US$5.8 billion. Of these, only one, Novantrone (mitoxantrone), is currently subject to generic competition in the US.
ADHD
The ADHD market had global sales of US$2.6 billion in 2005, and accounted for 3.8% of global CNS sales. Global sales for the drugs listed in this report were worth over US$2.8 billion, with the largest selling, Concerta (methylphenidate), having sales worth US$930 million.
INSOMNIA
The global market for insomnia products in 2005 was worth US$2.4 billion, and accounted for 3.5% of global CNS sales. In 2006, global sales for Ambien (zolpidem) were worth some US$2.7 billion. However, zolpidem has now been opened to generic competition in the US, with a number of companies gaining ANDA approvals for versions of the drug in 2007.
Among the 63 products evaluated in the report
- Abilify
- Aricept
- Azilect
- Carbatrol
- Copaxone
- Cymbalta
- Durotep
- Effexor
- Exelon
- Invega
- Keppra
- Lamictal
- Lyrica
- Namenda
- Prozac
- Rebif
- ReQuip
- Risperdal
- Seroxat
- Zoloft
- Zyprexa
Companies active in the CNS market are reviewed with respect to
- CNS Products
- Recent Product Approvals
- Financials
- Significant developments
Product samples
Detailed Table of Contents
Customers who bought this item also bought
Euro 2012 in Poland - Construction Investments
Euro 2012 in Poland - Construction Investments
Euro 2012 in Ukraine - Construction Investments
Euro 2012 in Ukraine - Construction Investments
E7: The Outlook for Pharmaceuticals to 2012
The Incumbent Telco in 2012
Cardiovascular Generic Drugs: Prospects and Opportunities to 2012
PVRs and HD in Europe and the US, 2006 - 2012 (Databook)
|
|
|
|
